Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 2.72B 2.37B 2.19B 2.05B 3.85B 256B 3.88B 26.03B 10.09B 126B 10.2B 9.98B 438B P/E 2026 *
-98.7x
P/E 2027 * 20.2x
Enterprise Value 2.72B 2.37B 2.19B 2.05B 3.85B 256B 3.88B 26.03B 10.09B 126B 10.2B 9.98B 438B EV / Sales 2026 *
3.9x
EV / Sales 2027 * 3x
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day+0.98%
1 week+1.95%
Current month+6.33%
1 month+3.05%
3 months-5.38%
6 months-22.41%
Current year-22.86%
1 week 60.08
Extreme 60.08
64.24
1 month 56
Extreme 56
65.27
Current year 56
Extreme 56
83.92
1 year 38.51
Extreme 38.51
85.25
3 years 12.57
Extreme 12.57
85.25
5 years 10.8
Extreme 10.8001
85.25
10 years 10.8
Extreme 10.8001
85.25
Manager TitleAgeSince
Chief Executive Officer 48 31/08/2018
Director of Finance/CFO 64 23/04/2023
Chief Tech/Sci/R&D Officer 47 03/11/2024
Director TitleAgeSince
Director/Board Member 72 17/02/2026
Director/Board Member 80 31/12/2016
Director/Board Member 71 18/11/2020
Date Insider Type Main position Quantity % Market Cap.
06-15Sell

Chief Financial Officer

-14,396 0.0335%
06-14Sell

Director

-12,500 0.0291%
06-14Sell

Director

-2,954 0.0069%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%+1.95%+53.79%+241.22% 2.72B
+0.33%-0.36%+18.76%-22.11% 62.05B
+0.20%-9.17%+58.39%+196.56% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
+7.62%+8.19%-51.27%-59.11% 39.06B
-1.05%-1.73%+55.35%-33.92% 29.02B
+3.50%+28.15%+151.81%-50.31% 25.38B
-0.78%-9.50%+43.87%+55.34% 19.62B
+1.74%-0.39%-2.93%+113.90% 16.89B
-0.05%+0.23%+61.48%+101.93% 15.89B
Average +0.86%+2.58%+42.66%+58.09% 30.67B
Weighted average by Cap. +0.78%+1.72%+36.82%+37.86%

Financials

2026 *2027 *
Net sales 696M 607M 562M 526M 987M 65.71B 993M 6.67B 2.59B 32.34B 2.61B 2.56B 112B 905M 789M 730M 684M 1.28B 85.35B 1.29B 8.67B 3.36B 42.01B 3.4B 3.32B 146B
Net income -28.48M -24.83M -23M -21.53M -40.37M -2.69B -40.62M -273M -106M -1.32B -107M -105M -4.59B 158M 138M 128M 119M 224M 14.9B 225M 1.51B 586M 7.34B 593M 580M 25.47B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Employees
370
Date Price Change Volume
18/06/26 63.16 $ +0.98% 402,143
17/06/26 62.55 $ +2.88% 462,277
16/06/26 60.80 $ -1.70% 718,792
15/06/26 61.85 $ -0.16% 502,415
12/06/26 61.95 $ -1.05% 267,322
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
63.16USD
Average target price
94.11USD
Spread / Average Target
+49.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!